Dimensional Fund Advisors LP Sells 253,126 Shares of Boston Scientific Corporation $BSX

Key Points

• Dimensional Fund Advisors LP reduced its stake in Boston Scientific Corporation by 5.2%, selling 253,126 shares during the first quarter, leaving them with approximately 4.66 million shares valued at $470.2 million.
• Other institutional investors, such as Capital World Investors and GAMMA Investing LLC, significantly increased their holdings in Boston Scientific, highlighting strong institutional interest in the stock.
• Analysts remain positive on Boston Scientific's prospects, with several firms raising their price targets, resulting in an average target price of $117.50 and a consensus rating of "Buy".

Dimensional Fund Advisors LP decreased its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 5.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,661,316 shares of the medical equipment provider's stock after selling 253,126 shares during the quarter. Dimensional Fund Advisors LP owned 0.32% of Boston Scientific worth $470,171,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in BSX. HM Payson & Co. raised its holdings in shares of Boston Scientific by 1.4% during the 1st quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after purchasing an additional 98 shares in the last quarter. Baldwin Investment Management LLC raised its holdings in shares of Boston Scientific by 1.2% during the 4th quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after purchasing an additional 102 shares in the last quarter. Park Square Financial Group LLC raised its holdings in shares of Boston Scientific by 5.2% during the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after purchasing an additional 103 shares in the last quarter. HHM Wealth Advisors LLC raised its holdings in shares of Boston Scientific by 13.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 103 shares in the last quarter. Finally, Evergreen Capital Management LLC raised its holdings in shares of Boston Scientific by 1.7% during the 4th quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock valued at $565,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Price Performance

NYSE:BSX traded up $0.5940 on Tuesday, reaching $103.6440. The stock had a trading volume of 5,229,138 shares, compared to its average volume of 7,573,115. The company has a market capitalization of $153.57 billion, a P/E ratio of 61.69, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. Boston Scientific Corporation has a 1-year low of $78.08 and a 1-year high of $108.94. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The stock has a fifty day moving average price of $103.62 and a 200-day moving average price of $102.09.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity at Boston Scientific

In other news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer directly owned 1,476,882 shares in the company, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 345,029 shares of company stock valued at $35,976,603 in the last three months. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BSX. Morgan Stanley lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. BTIG Research reissued a "buy" rating and issued a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday, April 23rd. Evercore ISI boosted their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Finally, Leerink Partners assumed coverage on shares of Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.